Eleanor Malone on Muck Rack

Eleanor Malone

Verified
  • Editor in Chief, Commercial Insights, Generics Bulletin
  • Editor in Chief, Commercial Insights, In Vivo
  • Editor in Chief, Commercial Insights, Scrip
London
As seen in: Generics Bulletin, In Vivo, Scrip, The Guardian, Mondaq, Citeline, HBW Insight, Medtech Insight, The Pink Sheet, AIS Health, Clinical Leader, Cell & Gene, Advancing RNA
Editor in Chief, Commercial Insights, Citeline - Scrip, In Vivo, Generics Bulletin - covering biopharma news and analysis. All views are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Eleanor

Contact Eleanor, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Eleanor Malone’s Biography

Read Full Bio →

Eleanor has been Editor of Scrip Intelligence since 2014. She has worked on the title since 2000, reporting and analysing all aspects of the global pharma industry from M&A and partnering, financial and strategy news and trends through R&D to market access, policy and regulation. She has also worked on Scrip’s sister publication Clinica Medtech Intelligence. She holds an MA in modern languages from the University of Edinburgh. Based in London, she appears regularly on TV and radio to discuss ma…

Articles

Moderna And Genevant/Arbutus Settle LNP Patent Dispute For $950m+

|
By Eleanor Malone 
| Scrip
Moderna Held Accountable For Infringing Patent With COVID-19 Vaccine The payout could increase to $2.25bn if Moderna loses and ongoing appeal that would shift $1.3bn in liability to US taxpayers, making it the largest patent settlement in pharma history. • Source: Shutterstock Roivant subsidiary Genevant Sciences and Arbutus Biopharma have secured a settlement of $950m upfront from Moderna for patent infringement by its COVID-19 vaccine, just days before a jury trial was due to start.
Open in Who Shared Issue with article?

RAPT Therapeutics, Inc.

|
By Eleanor Malone 
| Citeline
https://www.rapt.com/ Industry Biotechnology Pharmaceuticals Vaccines Other Names/Subsidiaries FLX Bio Scrip Scrip Asks... What Does 2026 Hold For Biopharma?
Open in Who Shared Issue with article?

20 Voices: What Does 2026 Hold For Biopharma?

|
By Eleanor Malone 
| Citeline
Keep up with strategy, innovation and evolving trends across life science industries.
Open in Who Shared View Duplicates (4) Issue with article?
See all 332 licensed articles (333 Total)

Actions

Share this page

Get in touch with Eleanor

Contact Eleanor, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified